Format

Send to

Choose Destination
Clin Genitourin Cancer. 2019 May 27. pii: S1558-7673(19)30154-5. doi: 10.1016/j.clgc.2019.05.016. [Epub ahead of print]

Drug-Drug Interactions in Prostate Cancer Treatment.

Author information

1
Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
2
Department of Urology, Medical University Innsbruck, Innsbruck, Austria. Electronic address: Isabel-maria.heidegger@i-med.ac.at.

Abstract

Polypharmacy is associated with an increased risk of drug-drug interactions (DDIs), which can cause serious and debilitating drug-induced adverse events. With a steadily aging population and associated increasing multimorbidity and polypharmacy, the potential for DDIs becomes considerably important. Prostate cancer (PCa) is the most common cancer in men and occurs mostly in elderly men in the Western world. Therefore, the aim of this review is to give an overview of DDIs in PCa therapy to better understand pharmacodynamic and pharm kinetic side effects as well as their interactions with other medications. Last, we explore potential future strategies, which might help to optimize treatment and reduce adverse events patients with polypharmacy and PCa.

KEYWORDS:

Adverse events; Drug-drug interaction; Pharmacodynamic; Polypharmacy; Prostate cancer

PMID:
31677899
DOI:
10.1016/j.clgc.2019.05.016

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center